Claims
- 1. An antiviral composition comprising a suitable carrier and a compound in an antivirally effective amount, the compound having the structure: ##STR9## wherein R.sub.1 and R.sub.1' are the same or different and each is an alkyl group, a phenyl group or a substituted derivative of a phenyl group;
- wherein R.sub.2 and R.sub.2' are the same or different and each is hydrogen, an unbranched alkyl group, a halide or a group having the structure ##STR10## wherein R is hydrogen, an alkoxide group, an alkyl group, or OH; wherein R.sub.3 and R.sub.3' are the same or different and each is hydrogen or an alkyl group;
- wherein X and X' are the same or different and each is a water soluble group having weak to intermediate ligand field strength; and
- Q.sup.31 is a soluble, pharmaceutically acceptable negative ion.
- 2. The antiviral composition of claim 1 wherein R.sub.1 and R.sub.1' are the same and each is a C.sub.1 -C.sub.5 alkyl group, a phenyl group or a substituted derivative of a phenyl group where each substituent is a halide, an alkyl group or a group having the structure ##STR11## where R is hydrogen, an alkoxide group, an alkyl group or OH; R.sub.2 and R.sub.2' are the same and each is a C.sub.1 -C.sub.3 alkyl group, a halide, hydrogen, or a group having the structure ##STR12## wherein R is H, CH.sub.3 or OH; R.sub.3 and R.sub.3' are the same and each is a C.sub.1 -C.sub.3 alkyl group; X and X' are the same and each is NH.sub.3 ; and Q.sup.- is Br.sup.- or Cl.sup.-.
- 3. The antiviral composition of claim 2 wherein the compound has a structure: ##STR13## wherein Ph is a phenyl group.
- 4. An antiviral composition comprising a pharmaceutically acceptable carrier and a complex in an antivirally effective amount, the complex comprising a Co(III) complex having an octahedral basal plane defined by four donor atoms A, which may be the same or different, and two axial ligand donor atoms B, which may be the same or different, said donor atoms having a ligand field strength equal to or less than CN.sup.-, said complex reacting with O.sub.2.sup.- to form a Co(III)-O.sub.2 adduct or oxidizing O.sub.2.sup.- to produce dioxygen and a Co(II) complex.
- 5. The composition of claim 4 wherein the complex has a quadridentate ligand L bound to the Co(III) through the donor atoms which imposes planarity on the octahedral basal plane.
- 6. The composition of claim 5 wherein the quadridentate ligand L and bonded Co(III) comprises a 6, 5, 6 ring system, said 6-membered ring of said 6, 5, 6 ring system being unsaturated.
- 7. The composition of claim 6 having the formula [CoL(B).sub.2 ].sup.n wherein B is selected from the group consisting of I.sup.-, Br.sup.-, Cl.sup.-, F.sup.-, OH.sup.-, C.sub.2 O.sub.4.sup.2-, H.sub.2 O, and NH.sub.3 ; and n is -1, 0, or +1.
- 8. A method for treating a subject having a disease caused by a virus comprising administering to the subject an antiviral effective amount of the composition of claim 1.
- 9. A method for treating a subject having a disease caused by a virus comprising administering to the subject an antiviral effective amount of the composition of claim 2.
- 10. A method for treating a subject having a disease caused by a virus comprising administering to the subject an antiviral effective amount of the composition of claim 3.
- 11. A method for treating a subject having a disease caused by a virus comprising administering to the subject an antiviral effective amount of the composition of claim 4.
- 12. A method for treating a subject having a disease caused by a virus comprising administering to the subject an antiviral effective amount of the composition of claim 5.
- 13. A method for treating a subject having a disease caused by a virus comprising administering to the subject an antiviral effective amount of the composition of claim 6.
- 14. A method for treating a subject having a disease caused by a virus comprising administering to the subject an antiviral effective amount of the composition of claim 7.
CROSS-REFERENCE TO RELATED APPLICATIONS
The present application is a continuation-in-part of U.S. application Ser. No. 07/279,417, filed on Dec. 2, 1988, now pending which, in turn, is a continuation-in-part of U.S. application Ser. No. 07/147,713, now U.S. Pat. No. 4,866,054 and U.S. application Ser. No. 07/147,714 now U.S. Pat. No. 4,866,053 both filed on Jan. 25, 1988, which, in turn, are continuation-in-parts of U.S. application Ser. No. 06/862,804, filed on May 13, 1986, now abandoned. The contents of U.S. application Ser. Nos. 07/279,417, 07/147,713, 07/147,714, and 06/862,804 are hereby incorporated by reference into the present disclosure.
The present invention relates to metallo-organic cobalt compounds and their use in the treatment of subjects for conditions and diseases caused by viruses and viral infections. It has been discovered that certain conditions and diseases, e.g., inflammation, burns, wounds, and diseases caused by bacteria and fungi in mammalian species can be treated with certain complexes of cobalt having the structure: ##STR3##
wherein R.sub.1 and R.sub.1' are the same or different and each is an alkyl group, a phenyl group or a substituted derivative of a phenyl group;
wherein R.sub.2 and R.sub.2' are the same or different and each is hydrogen, an unbranched alkyl group, a halide or a group having the structure ##STR4## wherein R is hydrogen, an alkoxide group, an alkyl group, or OH;
wherein R.sub.3 and R.sub.3' are the same or different and each is hydrogen or an alkyl group;
wherein X and X' are the same or different and each is a water soluble group having weak to intermediate ligand field strength; and
Q.sup.- is a soluble, pharmaceutically acceptable negative ion.
To date, however, such uses have been the only ones disclosed for these complexes.
Today, virus infections are known to be significant causes of morbidity and mortality in human and veterinary medicine. Many of these diseases are untreatable or the available therapies are not entirely satisfactory and only provide minimal clinical response. For the most part, it is known that viral diseases do not respond to therapy with conventional antibiotics. Despite some recent successes in the development of antiviral chemotherapeutic agents, new treatments for these diseases are needed to improve the management of viral infections in clinical medicine.
I have discovered that compounds having the structure of Formula I exhibit significant activity as antiviral agents. In addition, I have discovered that the compounds exhibit significant activity in comparison with known licensed antiviral agents. The compounds can be used for treating viral infections as is, or in a composition form when combined with a pharmaceutically acceptable carrier. Depending on the nature of the infection and the manner in which it manifests itself, the inventive antiviral compositions may be administered by using conventional modes of administration, e.g., oral, topical application, parenteral, and the like. The antiviral composition of the invention comprises a suitable pharmaceutically acceptable carrier and the inventive compound in an amount effective to suppress the replication and/or abort the infective life cycle of the virus causing the infection.
Foreign Referenced Citations (3)
| Number |
Date |
Country |
| 115130 |
Aug 1984 |
EPX |
| 1158279 |
Jul 1969 |
GBX |
| 1556204 |
Nov 1979 |
GBX |
Non-Patent Literature Citations (8)
| Entry |
| The Preparation and Some Properties of Cobalt(II) Schiff Base Complexes and Their Molecular Oxygen Adducts, Kashuga et al., Bull. Chem. Soc. Jpn., (1983), 56: 95-98. |
| The Preparation and Some Properties of Copper(II) and Nickel(II) Schiff Base Complexes Having Various Peripheral Substituent Groups, Nagara et al., Inorganic Chimica Acta, (1981), 47:37-40. |
| Action of N-Bromosuccinimide on Methane Carbons of N,N'-Bis(Benzoylacetone Ethylenediaminiatonickel(II) and Copper(II), Nagara et al., Inorg. Nucl. Chem. Letters, (1981), 17:235-237. |
| In-Plane Ligand Effects on Oxygenation of Cobalt(II) Schiff Base Complexes, Kasuga et al., Inorganic Chimica Acta, (1984), 84:113-116. |
| 3-Methylpentane-2,4-Dione, Johnson et al., Organic Synthesis Collective, vol. V, 785-86. |
| Spin-Pairing Model of Dioxygen Binding and its Application to Various Transition-Metal Systems as Well as Hemoglobin Cooperativity, Drago et al., Acc. Chem. Res., (1980), 13: 353-360. |
| Thermodynamics of Oxygen Binding in Natural and Synthetic Dioxygen Complexes, Niederhoffer et al., Chem. Rev., (1984), 84:137-203. |
| Assigning Oxidation States to Some Metal Dioxygen Complexes of Biological Interest, Summerville et al., Journal of Chemical Education, (1979), 56: 3. |
Related Publications (1)
|
Number |
Date |
Country |
|
147714 |
Jan 1988 |
|
Continuation in Parts (3)
|
Number |
Date |
Country |
| Parent |
279417 |
Dec 1988 |
|
| Parent |
147713 |
Jan 1988 |
|
| Parent |
862804 |
May 1986 |
|
Patent Grant
5106841
